Cardiff Oncology Reports Positive Phase 2 Data for Onvansertib in mCRC, Advances to Registrational Trial, and Announces Leadership Transition
CRDF is trading near its 52-week low of $1.85 (10% above the low) on elevated volume (11× avg).
Summary
Cardiff Oncology announced positive Phase 2 clinical trial results for onvansertib in RAS-mutated metastatic colorectal cancer, supporting advancement to a registrational program, alongside a leadership transition with the CEO and CFO stepping down.
Key Events · Product Development and Regulatory · CRDF
-
Positive Phase 2 Clinical Trial Results
Onvansertib demonstrated dose-dependent improvements in objective response rates (72.2% vs 43.2% SoC) and progression-free survival (HR 0.37 vs SoC, p=0.048) in first-line RAS-mutated metastatic colorectal cancer.
-
Advancement to Registrational Program
The 30 mg dose of onvansertib was selected for a registrational trial, with plans to initiate the program later in 2026 following FDA consultation.
-
CEO and CFO Departures
Dr. Mark Erlander (CEO) and James Levine (CFO) stepped down from their respective roles as part of a strategic leadership review.
-
Interim CEO Appointed
Dr. Mani Mohindru, a current Board member with extensive biotechnology executive experience, was appointed interim CEO.
Analysis · CRDF · Life Sciences
Cardiff Oncology announced highly positive Phase 2 clinical trial results for its lead candidate, onvansertib, in first-line RAS-mutated metastatic colorectal cancer. The data demonstrated dose-dependent improvements in objective response rates and progression-free survival, leading to the selection of a 30 mg dose for a registrational trial planned for later this year. This represents a significant advancement towards potential market approval in an area with high unmet medical need. Concurrently, the company announced a leadership transition, with the CEO and CFO stepping down. While such executive changes can introduce uncertainty, the appointment of an experienced interim CEO and the framing of the transition as aligning with late-stage development suggest a strategic move to capitalize on the promising clinical momentum. Investors should closely monitor the progress of the registrational trial and the search for permanent leadership.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 39.1% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134M. The 52-week trading range was $1.85 to $4.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.